![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD63 |
Gene summary for CD63 |
![]() |
Gene information | Species | Human | Gene symbol | CD63 | Gene ID | 967 |
Gene name | CD63 molecule | |
Gene Alias | LAMP-3 | |
Cytomap | 12q13.2 | |
Gene Type | protein-coding | GO ID | GO:0002090 | UniProtAcc | A0A024RB05 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
967 | CD63 | 047563_1562-all-cells | Human | Prostate | BPH | 3.14e-23 | -4.20e-01 | 0.0791 |
967 | CD63 | 048752_1579-all-cells | Human | Prostate | BPH | 1.62e-30 | -4.58e-01 | 0.1008 |
967 | CD63 | 052095_1628-all-cells | Human | Prostate | BPH | 4.06e-19 | -4.69e-01 | 0.1032 |
967 | CD63 | 052097_1595-all-cells | Human | Prostate | BPH | 7.21e-17 | -4.26e-01 | 0.0972 |
967 | CD63 | 052099_1652-all-cells | Human | Prostate | BPH | 6.05e-26 | -5.29e-01 | 0.1038 |
967 | CD63 | Dong_P1 | Human | Prostate | Tumor | 2.18e-06 | -3.63e-02 | 0.035 |
967 | CD63 | Dong_P3 | Human | Prostate | Tumor | 4.35e-12 | -2.22e-01 | 0.0278 |
967 | CD63 | Dong_P5 | Human | Prostate | Tumor | 5.70e-05 | -1.56e-01 | 0.053 |
967 | CD63 | P7 | Human | Prostate | Tumor | 8.69e-12 | 1.37e+00 | -0.1025 |
967 | CD63 | P9 | Human | Prostate | Tumor | 7.98e-03 | -1.55e-01 | -0.0285 |
967 | CD63 | P10 | Human | Prostate | Tumor | 2.19e-13 | 7.99e-01 | -0.0902 |
967 | CD63 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 7.65e-05 | -7.54e-01 | 0.1557 |
967 | CD63 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 1.54e-02 | -7.28e-01 | 0.1479 |
967 | CD63 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 3.52e-06 | -8.99e-01 | 0.1531 |
967 | CD63 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 5.86e-06 | -4.27e-01 | 0.1633 |
967 | CD63 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.90e-17 | -6.53e-01 | 0.1608 |
967 | CD63 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 3.90e-07 | -5.28e-01 | 0.1604 |
967 | CD63 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 3.99e-06 | -4.52e-01 | 0.1621 |
967 | CD63 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 3.36e-03 | -6.54e-01 | 0.159 |
967 | CD63 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.31e-10 | -5.96e-01 | 0.1602 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00068986 | Breast | Precancer | receptor-mediated endocytosis | 27/1080 | 244/18723 | 9.01e-04 | 1.03e-02 | 27 |
GO:00458076 | Breast | Precancer | positive regulation of endocytosis | 14/1080 | 100/18723 | 1.77e-03 | 1.74e-02 | 14 |
GO:00316235 | Breast | Precancer | receptor internalization | 15/1080 | 113/18723 | 2.11e-03 | 2.00e-02 | 15 |
GO:00482606 | Breast | Precancer | positive regulation of receptor-mediated endocytosis | 9/1080 | 52/18723 | 2.67e-03 | 2.36e-02 | 9 |
GO:00109596 | Breast | Precancer | regulation of metal ion transport | 37/1080 | 406/18723 | 4.07e-03 | 3.22e-02 | 37 |
GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
GO:000689813 | Breast | IDC | receptor-mediated endocytosis | 35/1434 | 244/18723 | 2.38e-04 | 3.75e-03 | 35 |
GO:004580713 | Breast | IDC | positive regulation of endocytosis | 18/1434 | 100/18723 | 5.40e-04 | 6.96e-03 | 18 |
GO:003162311 | Breast | IDC | receptor internalization | 19/1434 | 113/18723 | 9.17e-04 | 1.05e-02 | 19 |
GO:00431126 | Breast | IDC | receptor metabolic process | 23/1434 | 166/18723 | 4.04e-03 | 3.25e-02 | 23 |
GO:004826013 | Breast | IDC | positive regulation of receptor-mediated endocytosis | 10/1434 | 52/18723 | 5.49e-03 | 4.03e-02 | 10 |
GO:00301007 | Breast | IDC | regulation of endocytosis | 27/1434 | 211/18723 | 5.92e-03 | 4.26e-02 | 27 |
GO:000689823 | Breast | DCIS | receptor-mediated endocytosis | 35/1390 | 244/18723 | 1.31e-04 | 2.25e-03 | 35 |
GO:001095921 | Breast | DCIS | regulation of metal ion transport | 50/1390 | 406/18723 | 2.86e-04 | 4.22e-03 | 50 |
GO:003162321 | Breast | DCIS | receptor internalization | 19/1390 | 113/18723 | 6.30e-04 | 7.90e-03 | 19 |
GO:004580722 | Breast | DCIS | positive regulation of endocytosis | 17/1390 | 100/18723 | 1.05e-03 | 1.15e-02 | 17 |
GO:004311213 | Breast | DCIS | receptor metabolic process | 23/1390 | 166/18723 | 2.75e-03 | 2.41e-02 | 23 |
GO:004826021 | Breast | DCIS | positive regulation of receptor-mediated endocytosis | 10/1390 | 52/18723 | 4.41e-03 | 3.41e-02 | 10 |
GO:00482596 | Breast | DCIS | regulation of receptor-mediated endocytosis | 16/1390 | 110/18723 | 7.16e-03 | 4.85e-02 | 16 |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0520542 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa04142 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa041421 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052056 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa052057 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD63 | SNV | Missense_Mutation | rs11574657 | c.482N>T | p.Ser161Leu | p.S161L | P08962 | protein_coding | tolerated(0.22) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CD63 | SNV | Missense_Mutation | novel | c.635N>T | p.Gly212Val | p.G212V | P08962 | protein_coding | tolerated(0.3) | benign(0.393) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | c.486G>T | p.Lys162Asn | p.K162N | P08962 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CD63 | SNV | Missense_Mutation | novel | c.468N>C | p.Lys156Asn | p.K156N | P08962 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | c.457N>T | p.Asp153Tyr | p.D153Y | P08962 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
CD63 | SNV | Missense_Mutation | rs11574657 | c.482C>T | p.Ser161Leu | p.S161L | P08962 | protein_coding | tolerated(0.22) | benign(0.013) | TCGA-AA-A02Y-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | rs200393279 | c.358N>T | p.Arg120Trp | p.R120W | P08962 | protein_coding | deleterious(0.05) | possibly_damaging(0.773) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CD63 | SNV | Missense_Mutation | novel | c.467N>C | p.Lys156Thr | p.K156T | P08962 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | novel | c.206N>C | p.Phe69Ser | p.F69S | P08962 | protein_coding | deleterious(0.01) | possibly_damaging(0.724) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD63 | SNV | Missense_Mutation | novel | c.58N>A | p.Ala20Thr | p.A20T | P08962 | protein_coding | tolerated(0.23) | benign(0.014) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
967 | CD63 | CELL SURFACE, DRUGGABLE GENOME, KINASE | NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | 15608437 | ||
967 | CD63 | CELL SURFACE, DRUGGABLE GENOME, KINASE | NSAIDS | 15608437 |
Page: 1 |